Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pcDNA3 myc CIITA (P#808) Citations (4)

Originally described in: Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection.
Kanazawa S, Okamoto T, Peterlin BM Immunity. 2000 Jan . 12(1):61-70.
PubMed Journal

Articles Citing pcDNA3 myc CIITA (P#808)

Semaphorin 3A alters endothelial cell immunogenicity by regulating Class II transactivator activity circuits. Schlahsa L, Zhang H, Battermann A, Verboom M, Immenschuh S, Eiz-Vesper B, Stripecke R, Engelmann K, Blasczyk R, Figueiredo C. Transfusion. 2014 Aug;54(8):1961-70. doi: 10.1111/trf.12631. Epub 2014 Mar 28. PubMed
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Tveita A, Fauskanger M, Bogen B, Haabeth OA. Oncotarget. 2016 Oct 11;7(41):67175-67182. doi: 10.18632/oncotarget.11946. PubMed
Swine Leukocyte Antigen Class II Is a Xenoantigen. Ladowski JM, Reyes LM, Martens GR, Butler JR, Wang ZY, Eckhoff DE, Tector M, Tector AJ. Transplantation. 2018 Feb;102(2):249-254. doi: 10.1097/TP.0000000000001924. PubMed
HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. Jin YP, Valenzuela NM, Zhang X, Rozengurt E, Reed EF. J Immunol. 2018 Apr 1;200(7):2372-2390. doi: 10.4049/jimmunol.1701259. Epub 2018 Feb 23. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.